Products in Development
At INSYS, we're focused on developing and commercializing innovative drugs and novel drug delivery systems that improve the quality of patients' lives.
Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, we work to address the clinical shortcomings of existing commercial products.
Our product pipeline is concentrated on developing medicines that directly address areas of unmet medical needs, including pain, opioid dependence, reversal of opioid-induced respiratory depression, prevention of nausea and vomiting, and ovarian and gastric cancer.
In addition, our pipeline is purposed to address the significant unmet needs of severe pediatric epilepsies such as Dravet Syndrome, infantile spasms, and Lennox-Gastaut Syndrome.
| Compound | Area of Research | Status |
|---|---|---|
| Dronabinol Oral Solution | Nausea / Vomiting Associated with Cancer Chemotherapy and Anorexia / Weight Loss in Patients with AIDS |  |
| Buprenorphine Sublingual Spray | Moderate to Severe Pain |  |
| Naloxone Sublingual Spray | Reversal of Opioid Depression | |
| Cannabidiol | Severe Pediatric Epilepsies |  |
| Buprenorphine Naloxone Sublingual Spray | Opioid Dependence | |
| Ondansetron Sublingual Spray | Prevention of Nausea and Vomiting | |
| Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) | Cervical and Cholangiocarcinoma | |
COMPOUND
- Dronabinol Oral Solution
Area of Research
Nausea / Vomiting Associated with Cancer Chemotherapy and Anorexia / Weight Loss in Patients with AIDS
Phase
- Buprenorphine Sublingual Spray
Area of Research
Moderate to Severe Pain
Phase
- Naloxone Sublingual Spray
Area of Research
Reversal of Opioid Depression
Phase
- Cannabidiol
Area of Research
Severe Pediatric Epilepsies
Phase
- Buprenorphine Naloxone Sublingual Spray
Area of Research
Opioid Dependence
Phase
- Ondansetron Sublingual Spray
Area of Research
Prevention of Nausea and Vomiting
Phase
- Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)
Area of Research
Cervical and Cholangiocarcinoma
Phase
